Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.94% 7.60 7.20 8.00 7.75 7.60 7.75 111,250 16:22:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 16

Eden Research Share Discussion Threads

Showing 7251 to 7275 of 8275 messages
Chat Pages: Latest  295  294  293  292  291  290  289  288  287  286  285  284  Older
DateSubjectAuthorDiscuss
11/6/2019
07:56
Chrischas, could you elucidate what those figures actually mean, before I respond to them? I don't mean your general point, but the figures themselves. Thank you. I understand your underlying message.
brucie5
11/6/2019
07:53
Why has this company not been takenover by one of the big boys yet?
woolybanana
11/6/2019
07:25
Well they are THE only 2 benefitting out of the company.Thats a lot of money ,part of which could have been used to actually promote the company. The short ,mid and long term is going straight into their pockets.
chrischas
11/6/2019
07:17
My wife will be so pleased that the source of pinot grigio is being safe guarded ;-)
wan
11/6/2019
07:05
https://twitter.com/edenresearch/status/1138336756162605057There's actually a picture of someone using an EDEN product..whooo!
dplewis1
11/6/2019
06:37
Interesting, Wan, and thanks. Good to see Eden's views being included among the larger players.
brucie5
11/6/2019
05:14
Two excellent articles follow. The first article (a long read) includes key commentary from the large players and also includes a number of very interesting comments from Eden's CEO, Sean Smith, which when taken into context from what the larger players state, is very encouraging indeed - Agrow biologicals review 2019 10 Jun 2019 As in previous instalments of Agrow’s annual review of the biologicals sector, for the 2019 review Agrow talked with big crop protection companies as well as niche biological ones to get a balanced view on various factors influencing the sector. Full story - hTTps://agrow.agribusinessintelligence.informa.com/AG031409/Agrow-biologicals-review-2019 Staying with IPM - Hone Your IPM Skills in the New Biologicals Paradigm Jaclyn Sindrich By Jackie Pucci|10 June 2019 hTTps://www.agribusinessglobal.com/biopesticides/hone-your-ipm-skills-in-the-new-biologicals-paradigm/
wan
10/6/2019
23:35
Chriscas, Your post, 6403. I assume that is irony, right? For a tech driven company Eden's ascendency is poorly understood and severely undervalued as measured by the share price. Some might argue that sales are slow as your numbers allow for milestone payments included.
investingisatrickygame
10/6/2019
23:33
From Super's post, number 6400 hxxps://www.crophealthnorth.co.uk/wp-content/uploads/2019/03/EdwardsGwynn-CropTec-widescreen.pdf The global market for biopesticides in 2019 is $6 billion From Eden's 2018 AGM presentation "Globally, Eden is one of a few biocontrol companies with proven products and regulatory authorisation" Eden's market Cap is circa £22 million So which of the other 'few' global players has all the value & the sales? And what are their market caps? And how do they differ from Eden? It appears increasingly strange to me that Eden makes such statements and yet the divide between the statement and Eden's value is like a chasm. These things need better consideration and deeper explanation if people are to buy the Eden share price. In theory, based on Eden's statement and the 2019 market value then Eden should be priced at £'s, not pence. 'Professional' investors in the City have investment rules, will look for the onset of deep profits, dividends & more. Eden has thus far been unable to penetrate this market and Powerscourt have been unsuccessful in inducing that investment into Eden. Private investors don't have those rules, they look to get in early and cheap and they look for high capital growth and which point the 'professionals' step in and invest and the Pi's retreat, happy with their ROI. Eden still needs to address the latter and convince them to buy, something they continually demonstrate a lack of will to do
investingisatrickygame
10/6/2019
18:48
Eden Research a very profitable business : so sustainable ,so long term. 2012- 90k. 0k 2013- 95k. 0k 2014- 105k. 36k 2015- 122k. 317.5k 2016. 249k. 266.7k 2017. 216k. 258k 2018. 278k. 353k 1061000k. 123000k mid term and long term that is a great performance!Long may it continue!
chrischas
10/6/2019
16:30
Paulpaolo Small beer and not a share price invigorator. Nor are label extensions. The share price is abysmal and the share price is a manageable and important asset in Eden's portfolio. You become a Plc to use the share price to your advantage. Eden doesn't seem to recognise that.
investingisatrickygame
10/6/2019
15:47
All being well the nit treatment launch should be at the start of September in Britain, as promised at the proactive investor event earlier this year, and the American nit regulatory approval must be very close now.
paulpaolo
10/6/2019
13:11
Investing...To be fair, my thrust was different to yours, in that we know they are active regarding regulatory trials supporting label extensions on various crops, so that tweet should hopefully mean something, but without delivery of those label extensions, the market cares not! So, your mantra that they should shout/talk more about relevant context when product sales for 2018 were £1.6m, is irrelevant until the market can effectively see beyond what would be judged as just talk/hype. In short, we require delivery and tangible effect!
wan
10/6/2019
11:57
wan, I posted similar on the other board. That statement means absolutely nothing if it is not put into relevant context. Eden has been quoting this on their various presentations for years. So what, tell me what this means for Eden, their commercial partners AND their shareholders. Nobody buys what they don't understand and nobody buys shares for zero returns.
investingisatrickygame
10/6/2019
10:48
Yes, I have always thought that Sipcam has expectations for Mevalone 'way' beyond botrytis in grapes, but grapes provides a not insignificant market and excellent validation!
wan
10/6/2019
10:40
One of the Authors Dr Roma Gwynn runs Rational Biopesticide Services. hTTp://biorationale.co.uk/index.php Despite the chlorotic share price we can only hope that the potential of the Trials and commercial connections Eden are building will lead to future opportunities. hTTps://www.eventbrite.co.uk/e/future-of-agricultural-biosolutions-tickets-59689512940?utm_term=eventurl_text# hTTps://horticulture.ahdb.org.uk/roma-gwynn-biography Dr Roma Gwynn has an MSc in Technology for Crop Protection and a PhD in Insect Pathology from Reading University. She is a biopesticide specialist working in technology for 30 years, initially as an insect pathologist research scientist to working for commercial companies in biocontrol product development. She is now an independent specialist. Roma has taken a lead role in the EU and internationally in the development and registration of new biopesticide technologies including semi-chemical, botanical and microbial substances. Her expertise is in facilitating the process of getting biopesticide products onto the market, with particular expertise in efficacy. Roma is the editor of the ‘The Manual of Biocontrol Agents’ published by BCPC, Chair of the Endowment Committee for the Society of Invertebrate Pathology and a Biopesticide Consultant. Roma has participated in entomopathogenic nematode COST Actions 819 and 850 and is an active member of the International Biocontrol Manufacturers Association. Roma has been an expert for: the REBECA project for regulation of biocontrol agents, the OECD Biopesticide Steering Group and EU Commission. Roma has also been involved in the development of biopesticide regulatory guidance and is consultant on several biopesticide collaborative research, AGRI-TECH and PhD projects. ……………. hTTps://www.crophealthnorth.co.uk/timeline/
supersonico
10/6/2019
10:36
Yes, it has to be about label extensions, otherwise, from the figures I've seen, the market does not really justify Sipcam's interest in 3aey. Wouldn't you agree?
brucie5
10/6/2019
10:10
Super, A global biopesticide market right now worth $6 billion. We cannot get away from the facts and the focus must be Eden's share price and who is responsible for it. Eden has two global bio-active products sold by primary players in the agro-chemical market and has unique technology in Sustaine which is both currently used as a deliverable and also yet to be fully exploited with third parties for single use of their products or/and blending with Eden's active ingredients. COMPANY STATEMENTS The only bio-active/pesticide company listed in London. One of only a few biocontrol companies globally with proven products and regulatory approval. The last statement is bold and as such and if true, Eden's share price and market capitalisation is a disgrace relative to the current market size. I see nothing wrong in coming to this conclusion or banging on about it. Eden's share price has flatlined for 3 years. It is in a coma in real terms and being maintained on life support (loyal shareholders who are so far in the red they daren't sell). People are way too focused on the big blue sky opportunity whilst taking their eye off of value today. Rose tinted glasses does not put money in anyone's pocket today and this is so very typical of AIM stocks. Eden and their advisers should do much better.
investingisatrickygame
10/6/2019
09:31
Eden new tweeter friends Newcastle University who's partners include Bayer.. Newcastle University Dr Roma Gwynn Biopesticide Strategist Rationale. The end of industrial agrochemical spraying ? Environmental & health concerns The precautionary principle Decline in new MoA discovery (commercial) Resistance. Global market Increased Over 300% * 2008-2018 BIOPESTICIDES Global market 2019 value over $6 billion* Increase A shift to Biological agents - … hTTps://www.crophealthnorth.co.uk/wp-content/uploads/2019/03/EdwardsGwynn-CropTec-widescreen.pdf
supersonico
10/6/2019
08:24
I note Eden's tweet last week highlighting the effect of Botrytis on crops (other than grapes). We know the potential (beyond grapes) Eden, but you need to 'effectively' realise that potential, only then will the market/investors respond.......or was that a subtle heads-up with regard to Mevalone label extension? I am not of course expecting a reply to this forum, but readers will get the drift given my expectations for label extensions for Mevalone.
wan
08/6/2019
22:39
Tenuous is not the word I would use nor Rumour ..just an observation based Guess, like my parallel delay Guess .. but 'most dismal stock in my portfolio' certainly sums the share price up atm.
supersonico
08/6/2019
18:17
Haha, well Eden clearly wins the 'most dismal stock in my portfolio' award so I suppose any form of rumour is interesting, however tenuous!
dplewis1
08/6/2019
17:38
Not just Someone.. The Right one. All Guesses all the Time
supersonico
08/6/2019
16:35
Are you suggesting someone is subtly building a stake?
dplewis1
08/6/2019
16:22
Have you got a translation for that last post because I've got no idea what any of that means..
dplewis1
Chat Pages: Latest  295  294  293  292  291  290  289  288  287  286  285  284  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191122 17:55:19